Autopsy report · NCT01405573

Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma

“lack of enrolment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months before it started.
• Ran for about 5 years 8 months before it stopped.
• 35 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

National Cancer Institute, Naples

Sponsor type

University, hospital or other

Conditions

Advanced Adult Hepatocellular Carcinoma

Interventions

Best Supportive Care; sorafenib

Participants

35

Sites

25

Countries

Italy

Trials that died the same way

• Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
  “Poor enrolment” (84% match in meaning)
• Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)
  “Difficulty in enrolment” (79% match in meaning)
• Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
  “difficulty in the enrolment” (78% match in meaning)
• A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
  “Low enrolment” (78% match in meaning)
• Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor
  “Too low enrolment rate” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.